Collaboration and Licensing Agreements - Narrative (Details) $ in Thousands, $ in Millions, ¥ in Billions	1 Months Ended				3 Months Ended		9 Months Ended			71 Months Ended
	Mar. 31, 2018 USD ($)	Dec. 31, 2017 USD ($)	Nov. 30, 2017 USD ($)	Jun. 30, 2015 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2023 CAD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($)	Oct. 31, 2023 USD ($)	Sep. 30, 2023 JPY (¥)	Jul. 31, 2023 USD ($)	Apr. 30, 2023 USD ($)	Oct. 31, 2022 USD ($)	Apr. 30, 2022 USD ($) payment_tranche
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues					$ 56,391	$ 4,986	$ 90,093		$ 7,980
Licensing revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues					32,014	9	32,790		23
Product supply revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues					2,092	92	5,354		1,058
2017 KKC Agreement | Licensing revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues						0			0
2017 KKC Agreement | Product supply revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues					2,100	83	5,400		1,000
Fosun Agreement | Licensing revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues						0			0
Knight Agreement | Licensing revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues					0	0	0		0
KKC | 2017 KKC Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Upfront license fees			$ 30,000
Potential development milestones			$ 55,000
Total revenues										$ 35,000
Potential commercialization milestones					57,000		57,000			57,000		¥ 8.5
Fee receivable for reduction in royalty rate																$ 40,000
Number of payment tranches for fee receivable for reduction in royalty rate | payment_tranche																2
KKC | 2017 KKC Agreement | Licensing revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue to be received					20,000		20,000			20,000
Proceeds from milestone payments					30,000		30,000			30,000					$ 35,000
Fosun Pharma | Fosun Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential development milestones					5,000		5,000			5,000
Proceeds from milestone payments													$ 2,000
Upfront payment received		$ 12,000
Potential development and commercialization milestones							$ 113,000
Threshold percentage of net sales for tiered royalties							20.00%	20.00%
Fosun Pharma | Fosun Agreement | Subsequent event
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from milestone payments											$ 3,000
Knight | Knight Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Potential development milestones					700		$ 700			700
Upfront payment received	$ 2,300
Potential development and commercialization milestones							16,400	$ 22.2
METiS Therapeutics Inc | Licensing revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total revenues					800		800
Revenue to be received														$ 800
Proceeds from milestone payments														$ 243,000
AstraZeneca | AZ Termination Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percentage of royalty revenue				10.00%
Percentage of non-royalty revenue				20.00%
Maximum potential payment per agreement				$ 75,000
Aggregate cost of revenue recognized					23,900		23,900			23,900
Aggregate amount paid					18,300		18,300			$ 18,300
Cost of revenue					$ 5,700	$ 500	$ 8,700		$ 800